Navigation Links
Sponges as drugs

Dutch researcher Nicole de Voogd has investigated the possibilities for rearing sea sponges in Indonesia. Some of these sponges contain substances of interest to the pharmaceutical industry. As these are increasingly difficult to obtain, there is growing interest in alternative methods of exploitation, such as rearing sponges.

For her research, De Voogd described three new species of sponges and examined the interactions of four sponge species with possible spatial competitors. She discovered that as soon as certain sponge species grow over corals, the coral develops necrotic tissue. From this she concluded that the sponges concerned produce their bioactive substances to defeat spatial competitors. This is important, as in an environment without spatial competitors, such as in a sponge culture, a lower concentration of the substances of interest to the pharmaceutical industry might be produced.

Sponge culture

The researcher tried to rear 9 of the 151 species of sponge observed but was successful with only 3 species. Although the survival rates of these species were generally very high, the growth rates were very slow and unpredictable. Moreover, the reared sponges produced less of the biologically-active substances than their natural counterparts.

Although Indonesia has a very high diversity of sponge species, and therefore a large number of biologically-active substances with pharmaceutical potential, most of the species occur in relatively low densities compared to species in temperate areas. De Voogd discovered that as a result of this low natural density, surprisingly few Indonesian species are suitable for sea rearing.

Sea rearing

Sedentary marine invertebrates such as sponges, are an important source for a large variety of biologically-active substances. Until more advanced techniques such as chemical synthesis, genetic modification and sponge cell culture are realised, rearing in the sea remains the most reliable
'"/>

Source:Netherlands Organization for Scientific Research


Page: 1 2

Related biology news :

1. Researchers identify target for cancer drugs
2. MetaChip provides quick, efficient toxicity screening of potential drugs
3. Newly discovered pathway might help in design of cancer drugs
4. UNC launches study of liver injury caused by drugs
5. UCLA study assesses cost-effectiveness of Hepatitis B drugs
6. Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs
7. FDA approves more generic AIDS drugs
8. Virginia Tech group adds tools to DNA-targeted anti-cancer drugs
9. Scientists discover that three molecules may be developed into new Alzheimers drugs
10. Scientists to mimic nature for newest cancer drugs
11. Bacteria are key to green plastics, drugs
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Sponges drugs

(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/5/2014)... PROVO, Utah , Dec. 4, 2014  Tute ... has raised $2.3 million in Series A1 funding led ... angel investors also participated in the investment round. ... as the healthcare community adopts next-generation sequencing and seeks ... disease," said Reid Robison , MD MBA, and ...
(Date:12/3/2014)... Calif. , Dec. 2, 2014   ... globally deployed, innovative test solutions for military, aerospace, ... newest version of its successful TS-900 PXI ... performance and features of high-end systems to customers ... outstanding value compared to traditional ATE. ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... next generation of treatments for shock or stroke could be ... ?neuroglobin. In a review article to be published in the ... Rome describe this protein, which may be the key to ... for patients. , The Italian researchers suggest that neuroglobin is ...
... be used to return severely failing hearts to their ... according to new research. , The mechanical devices, known ... in patients with very severe heart failure whilst they ... England Journal of Medicine, shows that using an LVAD ...
... will fund a 5-year study examining why dead zones have ... allow them to detect the cause and stop the spread ... is a very serious problem," said University of Michigan's Donald ... and lead investigator of the project. "In the 1960s and ...
Cached Biology News:Mechanical 'artificial hearts' can remove need for heart transplant by returning heart to normal 2Researchers to study why dead zone returned to Lake Erie 2
(Date:12/19/2014)... ME (PRWEB) December 18, 2014 Ed ... director of the Center for Excellence in the Neurosciences ... New England, has been selected as a member of ... is the first neuroscientist from Maine to receive this ... nonprofit organization supported entirely by the Dana Foundation. ...
(Date:12/19/2014)... 2014 The empty capsules market ... ageing population and technological innovations in the empty ... are catalysing the growth of the empty capsules ... , Scope of Report , The report ... new entrants/smaller firms to gauge the pulse of ...
(Date:12/19/2014)... , Dec. 18, 2014   ISN ... & Safety Performance Indicators publication series. With ... of activity reported in 2013 within its online contractor ... and safety key performance indicator (KPI) statistics. ... Clients, U.S. publication is available in two ...
(Date:12/17/2014)... (PRWEB) December 16, 2014 “Never ... at Philipps- Universität Marburg’s Department of Physics, advises ... in the newly released SPIE Women in ... be too shy to ask questions.” , In ... engineering, and mathematics) occupations ranging from university professor ...
Breaking Biology Technology:UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3
... Exelixis,Inc. (Nasdaq: EXEL ) announced earlier today ... Deerfield Management. The arrangement will,be discussed by Exelixis management ... ET today, Thursday, June 5. To listen to a ... Investors at, http://www.exelixis.com ., A replay of the ...
... Anesiva,Inc. (Nasdaq: ANSV ) today announced that ... B Decoy (NF-kB Decoy) program, which includes the,clinical ... NF-kB Transcription Factor Decoy inhibits NF-kappa B, a ... as inflammatory,bowel disease (IBD), eczema, rheumatoid arthritis, and ...
... Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced ... Annual Global Healthcare Conference on Tuesday,June 10, at ... a live,webcast of the presentation on our website ... recommended that listeners log on 15 minutes early ...
Cached Biology Technology:Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program 2Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program 3
Sheep polyclonal to Salmonella Shoreditch ( Abpromise for all tested applications). Antigen: Native Salmonella shoreditch (Group D2)....
anti-achaete...
... Super-Sensitive, Super-Dark, Super-Small! ... with the ChemiDoc-It Imaging System. High-sensitivity ... produces low-background noise and wide dynamic ... a short exposure time. The light-tight ...
... Based Oligonucleotide) Genome Set and MEEBO (Mouse ... contain a collection of open source oligo ... allowing interrogation of thousands of genes. Developed ... University and UCSF, the sets enable the ...
Biology Products: